Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Health GroupHKSE:00673 24 Altman Z-Score is 1.42 as of Aug. 12, 2026. GuruFocus rates HKSE:00673 with a GF Score™ of 24/100 and a GF Value™ of HK$0.24 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 119 Medical Distribution companies, China Health Group ranks worse than 84.03% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 1.08 is in distress zone. This implies bankruptcy possibility in the next two years.
China Health Group has a Altman Z-Score of 1.42, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for China Health Group's Altman Z-Score or its related term are showing as below:
HKSE:00673'
s Altman Z-Score Range Over the Past 10 Years
Min: -4.42 Med: -2.91 Max: 2.46
Current: 1.08
During the past 13 years, China Health Group's highest Altman Z-Score was 2.46. The lowest was -4.42. And the median was -2.91.
China Health Group (HKSE:00673) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
China Health Group Altman Z-Score Related Terms
China Health Group Altman Z-Score Historical Data
* Premium members only.
The historical data trend for China Health Group's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:00673 vs MCK, COR, CAH: Altman Z-Score Comparison
For the Medical Distribution subindustry, China Health Group's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Health Group Altman Z-Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China Health Group's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where China Health Group's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
China Health Group's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.145
+
1.4
*
-1.0249
+
3.3
*
-0.3089
+
0.6
*
5.7371
+
1.0
*
0.2608
=
1.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
China Health Group (HKSE:00673) has a Altman Z-Score of 1.42 as of Aug. 12, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on China Health Group and its competitors. According to the industry distribution chart, China Health Group ranks #100 out of 119 companies in the Medical Distribution industry, placing it in the top 84%.
Is China Health Group's Altman Z-Score too high?
China Health Group's current Altman Z-Score is 1.42. The Medical Distribution industry median Altman Z-Score is 2.59. China Health Group's value of 1.42 is 45.2% below this industry median. Based on the distribution chart, China Health Group ranks #100 out of 119 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, China Health Group has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Health Group's Altman Z-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China Health Group ranks #100 out of 119 companies for Altman Z-Score. This places China Health Group in the lower half of its industry. The industry median Altman Z-Score is 2.59. China Health Group's value of 1.42 is 45.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Distribution company?
The median Altman Z-Score among Medical Distribution companies is 2.59, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Health Group's current Altman Z-Score of 1.42 is 45.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on China Health Group and its competitors. For the Medical Distribution industry, the median Altman Z-Score is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Health Group's current Altman Z-Score is 1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Health Group stock overvalued right now?
Based on GuruFocus' analysis, China Health Group (HKSE:00673) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.24, compared to a current price of HK$0.40 — trading 66.7% above its estimated fair value. The current Altman Z-Score is 1.42 and 45.2% below the Medical Distribution industry median of 2.59. China Health Group's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For China Health Group (HKSE:00673), the current Altman Z-Score is 1.42 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Health Group (HKSE:00673) Overvalued in 2026?
Based on GuruFocus' analysis, China Health Group stock appears to be overvalued.
The current stock price of HK$0.40 is trading 66.7% above its estimated GF Value™ of HK$0.24.
GuruFocus considers China Health Group to be Significantly Overvalued.
Key valuation signals for HKSE:00673:
Altman Z-Score: 1.42
GF Value™: HK$0.24 vs. price of HK$0.40 (66.7% above fair value)
Industry Position: 45.2% below the Medical Distribution median (#100 of 119)
No single metric tells the full story. See the HKSE:00673 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Health Group Ltd is an investment holding company. It is principally engaged in the distribution and service of medical equipment and consumables, provision of hospital operation and management services, and business factoring. It operates in the business in four segments: medical equipment and consumables distribution and service business; hospital operation and management services business; business service; and research and development and sale of functional food. It derives a majority of revenue from the Distribution and service in the medical equipment and consumables segment. Geographically, the group derives its revenue from the PRC.
24GF Score
Get the complete analysis for HKSE:00673
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00673 has been successfully added to your 
